Literature DB >> 21277173

The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.

Elizabeth N Holly1, Bree Ebrecht, Adam J Prus.   

Abstract

Agonists for neurotensin (NT)-1 receptors have produced antipsychotic-like effects in many animals, including reversal of prepulse inhibition deficits and psychostimulant-induced increases in spontaneous activity. The present study sought to provide a basic assessment of the putative antipsychotic effects of PD149163 in rats using a two way conditioned avoidance response task, which is highly validated for screening antipsychotic drugs, and an inclined grid assessment, which is used to assess extrapyramidal side effect liability. PD149163 (0.0625-8.0 mg/kg) significantly suppressed conditioned avoidance responding (CAR) following administration of a 1.0 or 8.0 mg/kg dose. PD149163 failed to significantly increase catalepsy scores. The typical antipsychotic drug haloperidol (0.01-1.0 mg/kg) significantly suppressed CAR at a 0.1, 0.3, and 1.0 mg/kg dose, and a significant increase in catalepsy scores was found at the 1.0 mg/kg dose. The atypical antipsychotic drug clozapine (2.5-10.0 mg/kg) also produced a significant inhibition of CAR, which occurred following administration of a 10.0 mg/kg dose. Clozapine failed to significantly increase catalepsy scores. Finally, D-amphetamine (1.0 mg/kg), serving as a negative control, failed to suppress CAR or increase catalepsy scores. These data further suggest that PD149163 may have atypical antipsychotic-like properties.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277173      PMCID: PMC3110992          DOI: 10.1016/j.euroneuro.2010.12.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  36 in total

1.  Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity.

Authors:  P Hertel; L Byskov; M Didriksen; J Arnt
Journal:  Eur J Pharmacol       Date:  2001-06-22       Impact factor: 4.432

2.  Evaluation of the effects of α2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats.

Authors:  Sarah M Jacobson; Adam J Prus
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

3.  Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

Authors:  P Hertel; M V Fagerquist; T H Svensson
Journal:  Science       Date:  1999-10-01       Impact factor: 47.728

4.  A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity.

Authors:  M Boules; L Warrington; A Fauq; D McCormick; E Richelson
Journal:  Eur J Pharmacol       Date:  2001-08-24       Impact factor: 4.432

5.  Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.

Authors:  B Cusack; M Boules; B M Tyler; A Fauq; D J McCormick; E Richelson
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

Review 6.  Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.

Authors:  Jes Gerlach
Journal:  Ann Clin Psychiatry       Date:  2002-03       Impact factor: 1.567

7.  The new generation of antipsychotic drugs: how atypical are they?

Authors:  Jeffrey M. Goldstein
Journal:  Int J Neuropsychopharmacol       Date:  2000-12       Impact factor: 5.176

8.  Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.

Authors:  David Feifel; Gilia Melendez; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2004-04       Impact factor: 7.853

9.  The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.

Authors:  Kimberly A Petrie; Michael Bubser; Cheryl D Casey; M Duff Davis; Bryan L Roth; Ariel Y Deutch
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more
  9 in total

1.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

2.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

3.  Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats.

Authors:  Todd M Hillhouse; Adam J Prus
Journal:  Eur J Pharmacol       Date:  2013-09-25       Impact factor: 4.432

4.  Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Authors:  Ashley A Keiser; Katelin S Matazel; Melissa K Esser; David Feifel; Adam J Prus
Journal:  Exp Clin Psychopharmacol       Date:  2014-09-15       Impact factor: 3.157

5.  Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.

Authors:  Adam J Prus; Todd M Hillhouse; Amber L LaCrosse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-23       Impact factor: 5.067

Review 6.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

7.  Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA/2J mice without causing excessive sedation.

Authors:  Amanda L Sharpe; Erika Varela; Michael J Beckstead
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

8.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

9.  Maternal separation enhances conditioned fear and decreases the mRNA levels of the neurotensin receptor 1 gene with hypermethylation of this gene in the rat amygdala.

Authors:  Hiroyuki Toda; Shuken Boku; Shin Nakagawa; Takeshi Inoue; Akiko Kato; Naoki Takamura; Ning Song; Masashi Nibuya; Tsukasa Koyama; Ichiro Kusumi
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.